Recursion Pharmaceuticals (RXRX) Cash & Equivalents (2020 - 2026)

Recursion Pharmaceuticals' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $654.5 million for Q1 2026.

• Quarterly Cash & Equivalents rose 30.78% year-over-year to $654.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $654.5 million (up 30.78% YoY) and the FY2025 annual result came in at $743.3 million, up 25.06% from the prior year.
• Cash & Equivalents was $654.5 million for Q1 2026 at Recursion Pharmaceuticals, down from $743.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $743.3 million in Q4 2025 and bottomed at $296.3 million in Q1 2024.
• A 5-year average of $500.0 million and a median of $474.3 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 137.23% — and 2024, when it plunged 37.37%.
• Recursion Pharmaceuticals' Cash & Equivalents stood at $549.9 million in 2022, then fell by 28.79% to $391.6 million in 2023, then surged by 51.79% to $594.4 million in 2024, then increased by 25.06% to $743.3 million in 2025, then slipped by 11.95% to $654.5 million in 2026.
• Business Quant data shows RXRX's Cash & Equivalents at $654.5 million in Q1 2026, $743.3 million in Q4 2025, and $659.8 million in Q3 2025.